Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

Core Viewpoint - Dianthus Therapeutics, Inc. has initiated a public offering of $400 million in common stock, with an additional option for underwriters to purchase up to $60 million more, aimed at advancing its clinical and preclinical development activities [1][2]. Group 1: Offering Details - The public offering consists of $400 million in shares of common stock or pre-funded warrants for certain investors [1]. - Underwriters will have a 30-day option to purchase an additional $60 million of shares at the public offering price [1]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Company Background - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharmaceutical executives [5].